StocksMedium•20 November 2026•
3 min read

Natural Alternatives’ Sales Fall to $28.121 Million as Quarterly Loss Widens

By

Key Facts

1Net sales were $28.121 million in the first quarter of fiscal 2027, compared with $37.730 million a year earlier.
2The net loss was $2.479 million, or $0.41 per diluted share, compared with $291,000 and $0.05 per share a year earlier.
3Gross margin fell to 4.5% from 11.7% in the comparable period.
4Debt of $10.0 million was reclassified as current liabilities as of September 30, 2026.
5Management expects a return to profitability in the fourth quarter of fiscal 2027.

Natural Alternatives International reported net sales of $28.121 million for the three months ended September 30, 2026, down from $37.730 million in the same period in 2025, according to its filing with the U.S. Securities and Exchange Commission. The company’s net loss widened to $2.479 million, or $0.41 per diluted share, compared with a loss of $291,000, or $0.05 per share, a year earlier. The revenue decline was accompanied by a drop in gross profit to $1.266 million from $4.397 million. Gross margin fell to 4.5% of sales from 11.7% in the comparable period. The results put weakness in contract manufacturing and lower factory utilization at the forefront of pressures facing the company in the first quarter of fiscal 2027.

The company said the sales decline was primarily tied to lower orders from several major customers amid excess inventories and delayed product launches. This reduced manufacturing volumes, lowering capacity utilization at the company’s facilities. Management said the operating loss in the first three months of fiscal 2027 was primarily due to underutilization of factory capacity. The decline in contract manufacturing also reduced gross profit and utilization of that capacity. The company said: "We incurred an operating loss during the first three months of fiscal 2027, primarily due to the underutilization of our plant capacities."

Not all revenue sources declined; royalty revenue from patents and trademarks rose 54% to $2.6 million from $1.7 million in the comparable period. The company attributed the increase primarily to higher TriBsyn sales, partly offset by lower sales of CarnoSyn raw materials. However, royalty growth did not prevent overall net sales from falling to $28.121 million from $37.730 million. Nor did it prevent gross margin from narrowing to 4.5% from 11.7%. The results showed that higher royalty revenue did not offset the effect of weak manufacturing on quarterly performance.

The pressures extended to the company’s credit position; it was not in compliance with the fixed-charge coverage requirement in its domestic credit agreement as of September 30, 2026, after U.S. sales came in below expectations. As a result, the company reclassified $10.0 million in debt, previously reported as long-term, as current liabilities. It said in its filing that it was in discussions with the lender about a waiver, amendment or other resolution. It also said that losses, negative operating cash flows and noncompliance with credit covenants raise substantial doubt about its ability to continue as a going concern for one year from the issuance of the financial statements. On September 30, 2026, cash, cash equivalents and restricted cash totaled $6.7 million, of which $6.3 million was held by the company’s Swiss subsidiary.

By contrast, the company said operating activities provided net cash of $1.2 million during the three months ended September 30, 2026, after using $4.0 million in the comparable period a year earlier. Management began consolidating production at a facility in Vista, California, and said the process had not disrupted production of customer products. It also began a comprehensive review of strategic alternatives, including a merger, acquisition, joint ventures or a sale of the company. Management expects net sales to increase in fiscal 2027 compared with fiscal 2026. It identified the fourth quarter of fiscal 2027 as the expected return to profitability.

Sources